Hold Rating on Amgen’s Maritide Amid Uncertainties in Efficacy and Tolerability
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...
Evan Seigerman Recommends Buy on Amgen Due to Promising MariTide Trial Results and Strategic Growth Moves
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...
The Globe and Mail48m
Stocks Slip Before the Open With Focus on Key U.S. Inflation Data and Trump’s Picks
December S&P 500 E-Mini futures (ESZ24) are down -0.18%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.33% this morning as investors digested Donald Trump’s latest cabinet appointments ...